Emblem Corp. and Dosecann Inc. Sign Licensing Deal to Develop Dosage-Controlled Formulations
TORONTO, Dec. 21, 2017 (GLOBE NEWSWIRE) — Emblem Corp. (TSX-V:EMC) (EMC.WT) (“Emblem” or the “Company”), has entered into a licensing agreement with Dosecann Inc. (“Dosecann”) pursuant to which Dosecann will begin developing a range of cannabinoid dosage formulations designed to ensure patients are better able to titrate and administer each dose the exact same way.
The two companies will begin work immediately on the development of a cannabis-oil oral spray dosage form, followed by the development of two separate dose-controlled vaporizers.
We are very excited about our relationship with Dosecann. We are focused on and committed to investing in pharmaceutical research and development and bringing more medically-focused products to market. We expect that these dosage-controlled products will have a major impact on the Canadian medical cannabis market and we’re looking forward to further collaborations with Dosecann to bring other value-added cannabis based metered-dosage forms to the market.
Nick Dean, President and CEO of Emblem Corp.
The licensing agreement involves a number of research related aspects including research into pre-clinical formulations, clinical development, as well as regulatory approval, manufacturing and the commercialization and distribution of a range of cannabinoid dosage forms.
The agreement provides for both Emblem and Dosecann to commercialize branded versions of the products, targeting specific markets and with different cannabinoid profiles.
Dosecann will receive royalty payments from Emblem on sales of Emblem-branded products and Emblem with receive royalties from Dosecann on sales of Dosecann-branded products.
There is substantial evidence that cannabinoids are effective for the treatment of a number of conditions including chronic pain, nausea, and spasticity in patients with Multiple Sclerosis. These advanced dosage forms and the whole strain extracts they contain are designed and formulated to enhance the therapeutic benefits available from medical cannabis.
John Stewart, President of Emblem’s Pharmaceutical Division
Emblem Corp. is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR (Access to Cannabis for Medical Purposes Regulations). Led by a team of cannabis experts and former health care and pharma executives, it has three distinct verticals – cannabis production, patient education centers, and pharmaceutical dosage form development. Emblem trades under the ticker symbol EMC on Toronto Venture Exchange (TSXV).
Dosecann Inc. is a PEI-based Licensed Dealer applicant currently completing the buildout of a 45,000 square foot GMP compliant facility. Within the purpose-built facility, Dosecann intends to accommodate product development, extraction, formulation, filling and packaging. Dosecann is developing a suite of cannabis products across a variety of delivery methods for both the medical and adult use markets.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.